4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      FDA's policy statement for the development of new stereoisomeric drugs.

      Chirality

      Adrenergic beta-Antagonists, chemistry, metabolism, pharmacokinetics, Animals, Biotransformation, Drug Design, Humans, Stereoisomerism, United States, United States Food and Drug Administration

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          1354468
          10.1002/chir.530040513

          Comments

          Comment on this article